Delivery Order SPE2DB22D1017-SPE2DB25FG9YF
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 29, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $10,324.90. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a single transaction under the company's broader pharmaceutical supply relationship with DLA. The award was not designated as a set-aside contract and was competitively awarded. Performance of...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.42 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single transaction within AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $44,402.40 on August 4, 2025, by the Defense Logistics Agency's Medical Supply Chain. This firm fixed-price, non-set-aside contract is a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order is scheduled for completion by August 5, 2025, with performance at the contractor's Corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,018.16 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This firm fixed-price contract, awarded on July 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation, and performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $13,321.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count packages) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in...
- This firm fixed price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $8,178.15, is for the delivery of Otezla 30 mg tablets over a period ending on April 8, 2024. Amerisourcebergen Drug Corp is a prime contractor that provides a wide range of pharmaceutical products and medical supplies to U.S. government agencies, including the Department of Defense....
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $17,697.48 by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price contract represents a child award under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be performed at the awardee's...
- The Defense Logistics Agency awarded a delivery order valued at $43,473.13 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60 count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting federal pharmaceutical procurement needs. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order contract valued at $9,084.36 by the Defense Logistics Agency's Medical Supply Chain on August 4, 2025, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The delivery order will be performed at the...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9YFDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,235.58 by the Defense Logistics Agency for 60 tablets of Otezla 30 mg on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitive award utilized firm fixed pricing with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The delivery order represents a routine pharmaceutical procurement supporting federal military and healthcare operations. AmerisourceBergen Drug Corp serves as a critical vendor within the Defense Logistics Agency's Medical Supply Chain, leveraging its IDC to fulfill immediate pharmaceutical needs across multiple therapeutic domains. The $999.9 billion parent contract enables the company to supply brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide, including services to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 8/15/25 |